DOI: Published online: December 1, 2016 1 Division of Pediatric Hemato-oncology, Department of Pediatrics, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea 2 Department of Pediatric Hematology and Oncology, Yonsei Cancer Center, Yonsei University Health System, Seoul, Korea 3 Department of Pathology, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea 4 Division of Medical Oncology, Department of Internal Medicine, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea 5 Department of Orthopedic Surgery, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea 6 Department of Radiation Oncology, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea Correspondence: Jung Woo Han, MD Division of Pediatric Hematology and Oncology, Department of Pediatrics, Yonsei University Health System, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea Tel: 82-2-2228-2060 Fax: 82-2-393-9118 E-mail: [email protected] Received: June 27, 2016 Accepted: October 9, 2016 Copyright 2017 by the Korean Cancer Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
Trends in Biotechnology 32 (1): 3245
Gastroenterology 149 , 15411552.e12 (2015)
Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis
In some embodiments, the otic formulation or composition comprises between about 0.1% to about 40% by weight of the therapeutic agent, or pharmaceutically acceptable prodrug or salt thereof
Dermatology 41, 788794
